九强生物1月9日获融资买入1002.61万元，融资余额1.95亿元

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance and financial metrics indicate a challenging period, with a notable decline in revenue and net profit year-on-year [2][3] - On January 9, Jiukang Bio's stock rose by 0.59%, with a trading volume of 87.04 million yuan, and a net financing buy of -2.81 million yuan, indicating a higher level of financing compared to the past year [1] - As of January 9, the total margin balance for Jiukang Bio was 195 million yuan, accounting for 2.45% of its market capitalization, which is above the 70th percentile of the past year [1] Group 2 - As of September 30, the number of Jiukang Bio's shareholders decreased by 2.48% to 18,100, while the average circulating shares per person increased by 2.54% to 23,502 shares [2] - For the period from January to September 2025, Jiukang Bio reported a revenue of 1.012 billion yuan, a year-on-year decrease of 18.24%, and a net profit attributable to shareholders of 272 million yuan, down 27.03% year-on-year [2] - Jiukang Bio has distributed a total of 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3]